RAC 6.08% $3.49 race oncology ltd

Progress of Israel R/R AML trial

  1. 8,933 Posts.
    lightbulb Created with Sketch. 18633
    Created this new thread to keep the Chart thread on-topic.

    ( see this post for background: https://hotcopper.com.au/posts/42690928/single )

    From clinicaltrials.gov first patient was effectively enrolled 19 July 2019.


    Screen Shot 2020-02-01 at 2.15.13 pm.png

    Then we had ASX announcement 25 July 2019. Announcement occurred after completion of first 7-days of treatment (with no complications).


    Screen Shot 2020-02-01 at 2.18.35 pm.png

    Reading the study design they first receive a 7-day course of Bisantrene,. There is also a 3-day consolidation treatment after Complete Response (optional).

    Screen Shot 2020-02-01 at 2.25.14 pm.png

    @RaceOncology reading the two historic paediatric cases with long term survival I note one patient received a lower dose 5-day course at 200mg/m2/day and the other received a 7-day 250mg/m2/day course.

    In the investigator-lead trial they are going for a longer 7-day course plus an additional optional 3-day consolidation course. That additional consolidation course is interesting ... seems to be like a booster measure to minimise risk of relapse.

    Has the 3-day consolidation course been added due to specific findings from previous Phase II studies?

    Screen Shot 2020-02-01 at 1.05.10 pm.png
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Mkt cap ! $462.1M
Open High Low Value Volume
$3.31 $3.53 $3.19 $3.477M 1.032M

Buyers (Bids)

No. Vol. Price($)
2 3880 $3.47

Sellers (Offers)

Price($) Vol. No.
$3.49 21891 2
View Market Depth
Last trade - 16.10pm 26/02/2021 (20 minute delay) ?
0.200 ( 4.62 %)
Open High Low Volume
$3.30 $3.49 $3.20 66180
Last updated 15.58pm 26/02/2021 (live) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.